Trial Profile
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Peposertib (Primary) ; Cisplatin
- Indications Cancer metastases; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors EMD Serono; EMD Serono Research & Development Institute
- 06 Apr 2022 Status changed from active, no longer recruiting to completed.
- 17 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2021 Planned End Date changed from 16 Dec 2020 to 19 Nov 2021.